Dolutegravir/lamivudine/tenofovir disoproxil

Dolutegravir/lamivudine/tenofovir disoproxil is a fixed-dose combination antiretroviral medication used in the treatment of HIV/AIDS. It combines three active ingredients: dolutegravir, lamivudine, and tenofovir disoproxil.

Composition

The medication is composed of three active ingredients. Dolutegravir is an integrase inhibitor, which prevents the virus from integrating its genetic material into the host cell. Lamivudine is a nucleoside reverse transcriptase inhibitor (NRTI), which blocks a critical step in the virus's replication process. Tenofovir disoproxil is a prodrug of tenofovir, an antiretroviral of the nucleotide analogue reverse transcriptase inhibitor (NtRTI) class.

Usage

Dolutegravir/lamivudine/tenofovir disoproxil is used in the treatment of HIV/AIDS. It is taken orally, usually once a day. The medication is used in combination with other antiretroviral drugs as part of an antiretroviral therapy (ART) regimen.

Side Effects

Common side effects include nausea, diarrhea, and headache. Serious side effects may include liver problems, lactic acidosis, and reactivation of hepatitis B in those previously infected.

Interactions

Dolutegravir/lamivudine/tenofovir disoproxil can interact with other medications, including other antiretrovirals, antacids, and certain anti-seizure medications. It is important to discuss all medications and supplements with a healthcare provider before starting treatment.

See Also

• Antiretroviral therapy
• HIV/AIDS
• Integrase inhibitor
• Nucleoside reverse transcriptase inhibitor
• Prodrug

This HIV related article is a stub. You can help WikiMD by expanding it.